





# Content

|                             |     |
|-----------------------------|-----|
| List of Abstracts by number | 2   |
| Abstracts                   | 13  |
| List of Main Authors        | 224 |




## Abstracts

### 3-SUBSTITUTED 2-OXINDOLE DERIVATIVES AS POTENTIAL ANTI-DIABETIC AND ANTITUMOR AGENTS

**Elena Bezsonova (1), Natalia Lozinskaya (1), Ekaterina Zaryanova (1), Michael Tsymlyakov (1), Alexander Efremov (1), Maria Salykina (1), Denis Babkov (2), Alexander Spasov (2)**

1) Lomonosov Moscow State University, Department of Chemistry, Leninskie Gory St., 1, Moscow, 119234, Russia  
2) Research Institute of Pharmacology, Volgograd State Medical University, KIM St. 20, 400001, Volgograd, Russia

Inhibition of glycogen synthase kinase 3 $\beta$  (GSK-3 $\beta$ ) is a new and widely investigated approach to the treatment of diabetes mellitus [a], cancer and Alzheimer's disease. We report the synthesis of novel GSK-3 $\beta$  inhibitors with pronounced antioxidant, anti-inflammatory and antitumor activity [b]. Over 50 3-substituted 2-oxindole derivatives were synthesized and tested *in vitro* against GSK-3 $\beta$  and  $\alpha$ -glucosidase, another molecular targets linked with diabetes [c].



The convenient choice of 2-oxindole scaffold allowed for the wide range of substituent variation which resulted in the possibility of effective and selective binding to both molecular targets. Lead compounds were shown to inhibit GSK-3 $\beta$  and  $\alpha$ -glucosidase in a cell-based assay with IC<sub>50</sub> 4.19 nM and 6.78  $\mu$ M respectively with low cytotoxicity.

Oral glucose tolerance test in rat model of type 2 diabetes mellitus demonstrated prominent antihyperglycemic activity of 3-substituted 2-oxindole derivatives.




Fig. 1. Effect of compound 1a and DPP-4 inhibitor vildagliptin on glucose response during an oral glucose tolerance test in HFD+STZ diabetic rats.




Fig. 2. Assessment of cytotoxicity in human PBMCs

GSK-3 $\beta$  inhibitors are proven to successfully combat systemic inflammatory process and oxidative stress, factors crucial in the development of type-2 diabetes [d]. Obtained substances were able to significantly reduce iNOS activity in LPS-induced macrophages, showcasing their anti-inflammatory properties. Novel 3-arylidene 2-oxindole derivatives were tested *in vitro* on lung adenocarcinoma (A549) and colon cancer (HCT116) cell lines and displayed cytotoxicity in the low micromolar range. Key substitutes were found both for compounds exhibiting cytotoxicity in the low micromolar range and compounds with antidiabetic properties.

#### References

- Biochemical Pharmacology, 2013, Vol. 86, no 2, P. 191-199.
  - Bioorganic & Medicinal Chemistry, 2019, Vol. 27, no 9, P. 1804-1817
  - Clinical and Investigative medicine, 1995, Vol. 18, no 4, P. 303-311
  - Journal of Diabetes Investigation, 2010, Vol. 1, no 3, P. 90-96
- (Acknowledgments ) This work was supported by the Russian Foundation for Basic Research (Project 20-03-00915A)